Johnson & Johnson to Host Investor Conference Call on First-Quarter Results
11 Março 2024 - 5:30PM
Business Wire
Johnson & Johnson (NYSE: JNJ) will host a conference call
for investors at 8:30 a.m. (Eastern Time) on Tuesday, April
16th to review first-quarter results. Joaquin Duato, Chairman
and Chief Executive Officer, Joseph J. Wolk, Executive Vice
President and Chief Financial Officer and Jessica Moore, Vice
President, Investor Relations will host the call. The question and
answer portion of the call will also include additional members of
Johnson & Johnson’s executive team.
Investors and other interested parties can access the
webcast/conference call in the following ways:
- The webcast and presentation material are accessible at Johnson
& Johnson’s website www.investor.jnj.com. A replay of the
webcast will be available approximately three hours after the
conference call concludes.
- By telephone: for both “listen-only” participants and those
financial analysts who wish to take part in the question-and-answer
portion of the call, the telephone dial-in number in the U.S. is
877-869-3847. For participants outside the U.S., the dial-in number
is 201-689-8261.
- A replay of the conference call will be available until
approximately 12:00 a.m. on April 30th. The replay dial-in number
for U.S. participants is 877-660-6853. For participants outside the
U.S., the replay dial-in number is 201-612-7415. The replay
conference ID number for all callers is 13744844.
- The press release will be available at approximately 6:45 a.m.
(Eastern Time) the morning of the conference call.
- Please refer to www.investor.jnj.com for a complete list of
currently planned earnings webcast/conference calls. Please
note the second-quarter date of Wednesday, July 17th, 2024.
About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our
strength in healthcare innovation empowers us to build a world
where complex diseases are prevented, treated, and cured, where
treatments are smarter and less invasive, and solutions are
personal. Through our expertise in Innovative Medicine and MedTech,
we are uniquely positioned to innovate across the full spectrum of
healthcare solutions today to deliver the breakthroughs of
tomorrow, and profoundly impact health for humanity. Learn more at
https://www.jnj.com/.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240311271898/en/
Media contact: media-relations@its.jnj.com Investor
contact: investor-relations@its.jnj.com
Johnson and Johnson (NYSE:JNJ)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Johnson and Johnson (NYSE:JNJ)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024